Naquotinib Inhibitor

Name: Naquotinib Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5764349
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5764349

Naquotinib (ASP8273) is an orally available, mutant-selective and irreversible EGFR inhibitor; (IC50s: 8-33nM and 230nM toward EGFR mutants and EGFR. More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Naquotinib, Inhibitor

Full Product Name

Naquotinib

Product Synonym Names

ASP8273

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

562.71

Solubility

DMSO: 40mg/mL (71.08mM)
Ethanol: 80mg/mL (142.16mM)
Water: Insoluble
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C30H41N8O3

SMILES

O=C(C1=NC(CC)=C(O[C@]2CN(C(C=C)=O)CC2)N=C1NC3=CC=C(N4CCC(N5CCN(C)CC5)CC4)C=C3)N

CAS Number

1448232-80-1

In Vitro

In NCI-H1975 (L858R/T790M), HCC827 (del ex19) and PC-9 (del ex19) xenograft models, oral Naquotinib treatment,dose-dependently induces tumor regression. Dosing schedules do not affect the efficacy of Naquotinib. In an NCI-H1975 xenograft model, complete regression of tumor is achieved after 14-days of Naquotinib treatment, Complete regression is maintained in 50% of mice more than 85 days after cessation of Naquotinib treatment,[2].

Product Categories/Family for Naquotinib, inhibitor

Angiogenesis; EGFR; JAK/STAT signaling; Tyrosine Kinase/Adaptors

Product References and Citations for Naquotinib, inhibitor

Sakagami H, et al. ASP8273, a novel mutant-selective irreversible EGFR inhibitor, inhibits growth of non-small cell lung cancer (NSCLC) cells with EGFR activating and T790M resistance mutations. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1728. doi:10.1158/1538-7445. AM2014-1728
Sakagami H, et al. ASP8273, a novel mutant-selective irreversible EGFR inhibitor, inhibits growth of non-small cell lung cancer (NSCLC) cells with EGFR activating and T790M resistance mutations. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1728. doi:10.1158/1538-7445. AM2014-1728
Konagai S, et al. ASP8273 selectively inhibits mutant EGFR signal pathway and induces tumor shrinkage in EGFR mutated tumor models. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2586. doi:10.1158/1538-7445. AM2015-2586
Konagai S, et al. ASP8273 selectively inhibits mutant EGFR signal pathway and induces tumor shrinkage in EGFR mutated tumor models. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2586. doi:10.1158/1538-7445. AM2015-2586

Other Notes

Small volumes of Naquotinib, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Naquotinib purchase

MBS5764349 is an inhibitor targeting Naquotinib.